Iyoda T, Nagamine Y, Nakane Y, Tokita Y, Akari S, Otsuka K
PLoS One. 2016; 11(9):e0162525.
PMID: 27622612
PMC: 5021278.
DOI: 10.1371/journal.pone.0162525.
Kang F, Chen P, Pan B, Lai M, Chen Y, Huang B
Onco Targets Ther. 2015; 8:2345-60.
PMID: 26366090
PMC: 4562734.
DOI: 10.2147/OTT.S87010.
Yashiro M, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T
Br J Cancer. 2013; 109(10):2619-28.
PMID: 24129235
PMC: 3833223.
DOI: 10.1038/bjc.2013.638.
Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T
Cancer Sci. 2009; 100(12):2402-10.
PMID: 19764996
PMC: 11159178.
DOI: 10.1111/j.1349-7006.2009.01315.x.
Beppu T, Yoshida Y, Arai H, Wada T, Suzuki M, Ogawa A
J Neurooncol. 2001; 49(3):213-8.
PMID: 11212900
DOI: 10.1023/a:1006486528418.
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Taron M, Plasencia C, Abad A, Martin C, Guillot M
Invest New Drugs. 2000; 18(2):139-47.
PMID: 10857993
DOI: 10.1023/a:1006325929424.
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Hong R, Sheen T, Ko J, Hsu M, Wang C, Ting L
Br J Cancer. 1999; 80(12):1962-7.
PMID: 10471046
PMC: 2363155.
DOI: 10.1038/sj.bjc.6690627.
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Teicher B, Holden S, Khandakar V, Herman T
J Cancer Res Clin Oncol. 1993; 119(11):645-51.
PMID: 8394365
DOI: 10.1007/BF01215982.
EPIC: an effective low toxicity regimen for relapsing lymphoma.
Hickish T, Roldan A, Cunningham D, Mansi J, Ashley S, Nicolson V
Br J Cancer. 1993; 68(3):599-604.
PMID: 8353050
PMC: 1968387.
DOI: 10.1038/bjc.1993.393.
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz G, Teicher B, Eder Jr J, Korbut T, Holden S, Ara G
Cancer Chemother Pharmacol. 1993; 32(6):455-62.
PMID: 8258194
DOI: 10.1007/BF00685890.
Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas.
Stewart D, Dahrouge S, Wee M, Aitken S, Hugenholtz H
J Neurooncol. 1995; 24(2):189-94.
PMID: 7562006
DOI: 10.1007/BF01078489.
Current development of podophyllotoxins.
Canetta R, Hilgard P, Florentine S, Bedogni P, Lenaz L
Cancer Chemother Pharmacol. 1982; 7(2-3):93-8.
PMID: 7044596
DOI: 10.1007/BF00254528.
[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].
Schmoll H, Niederle N, Achterrath W
Klin Wochenschr. 1981; 59(21):1177-88.
PMID: 7031350
DOI: 10.1007/BF01721212.
Intracavitary chemotherapy for malignant disease confined to body cavities.
Markman M
West J Med. 1985; 142(3):364-8.
PMID: 3887760
PMC: 1306028.
Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.
Collins C, Higano C, Livingston R, Griffin B, Keppen M, Miller T
Cancer Chemother Pharmacol. 1989; 24(2):128-32.
PMID: 2543513
DOI: 10.1007/BF00263134.
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Fischel J, Formento P, Etienne M, Gioanni J, Frenay M, Deloffre P
Cancer Chemother Pharmacol. 1990; 25(5):337-41.
PMID: 2306793
DOI: 10.1007/BF00686233.
Proliferative activity following induction chemotherapy in squamous cell carcinoma of the head and neck. A histopathological and immunohistochemical study using monoclonal antibodies.
Bettinger R, Loerz M
Eur Arch Otorhinolaryngol. 1991; 248(4):236-41.
PMID: 1713465
DOI: 10.1007/BF00173663.
